France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines. ...

Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarter Vaccines sales decreased by 7.8% to €3.4 billion, from lower influenza sales Research and Development expenses were €1.8 billion, an increase of 4.9% Selling, general and admin ...

Sanofi is set to release its quarterly earnings on October 24, 2025, with an expected EPS of $1.60 and revenue of approximately $12.4 billion.The company's recent success with efdoralprin alfa in the ElevAATe phase II study highlights its commitment to innovation and potential market growth.Financial metrics such as a P/E ratio of 11.66, enterprise value to operating cash flow ratio of 54.30, and a current ratio of 1.27 indicate Sanofi's stable financial position and market valuation.Sanofi (NASDAQ:SNY) is ...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the Medidata Patient, Data, and Study Experiences, building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally. The Medida ...

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care New York – Oct. 23, 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research ...

Key Takeaways Sanofi's ElevAATe study showed that efdoralprin alfa met all primary and key secondary endpoints.Efdoralprin alfa achieved higher functional AAT levels versus weekly plasma-derived therapy.The therapy's Q3W and Q4W dosing regimen may enhance convenience for AATD patients.Sanofi (SNY) announced that the phase II ElevAATe study, which evaluated its pipeline candidate, efdoralprin alfa, for the treatment of alpha-1 antitrypsin deficiency (AATD) emphysema, met all primary and key secondary endpoin ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

央视网消息：2025年以来，我国继续加大创新投入，推动新兴领域投资扩产，促进新质生产力形成。在这个过程中，外资企业也持 续加码投资中国、深化全产业链布局，对中国经济韧性与市场机遇投下信任票。 当前，中国汽车工业在向智能化和电动化加速转型，吸引了海外零部件供应商加大创新投入。总部位于法国的汽车零部件供应商法 雷奥集团2025年第三季度在上海竣工投产的新制造基地，专注于智能辅助驾驶领域，生产包括智能驾驶摄像头、域控制器、激光雷 达等产品。在法雷奥集团首席执行官佩里亚看来，中国在推动汽车零部件厂商技术持续升级方面发挥着重要力量。 数据显示，中国电扶梯保有量全球第一，在用电梯超过1100万部。其中，服役超过15年的电扶梯超过90万台，形成了一个庞大的更 新改造市场。截至2025年三季度末，美国电梯和自动扶梯制造商奥的斯参与的中国住宅电梯更新项目覆盖34个城市，深度融入了当 地的民生工程建设。 奥的斯全球公司董事会主席首席兼首席执行官朱蒂表示，如今全球人口老龄化、建筑适老化趋势不断加深，这是世界各地面临的共 同课题，在中国市场尤为显著。中国是奥的斯全球最大的电梯生产基地和全球最大的电梯市场，也有最大的数字化服务网络，他 ...

Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-modifying therapy to delay the progression of stage 3 T1D in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1DTzield is also being reviewed under the accelerated approval program Paris, October 20, 2025. The US Food and Drug Administration (FDA) has accepted for exped ...